Mount Sinai Microbiome Lab Joins NIH’s Accelerating Medicines Partnership
Lab will be part of a “hub” for studying role of microbiome in autoimmune diseases
The National Institutes of the Health (NIH) has awarded researchers at the Icahn School of Medicine at Mount Sinai a four-year grant to study the role of the human microbiome in rheumatoid arthritis, systemic lupus, and other autoimmune diseases. The grant is part of the NIH’s Accelerating Medicines Partnership® Autoimmune and Immune-Mediated Diseases (AMP® AIM) program, which is designed to speed the discovery of new treatments and diagnostics. It will support the Microbiome Technology and Analytic Center Hub (Micro-TEACH), a multidisciplinary team of researchers at Icahn Mount Sinai and NYU Langone Health.
“Every day, millions of people experience the pain and suffering caused when the immune system attacks the body. A growing body of research shows that a person’s microbiome—the bacteria found in the gut and other parts of the body—may play an important role in many of these attacks,” said Jose C. Clemente, PhD, Associate Professor of Genetics and Genomic Sciences at Icahn Mount Sinai and a leader of the team receiving the award. “We hope that by joining the NIH’s AMP AIM program we can speed the development of new treatments and diagnostic markers and thus reduce the suffering experienced by patients who have autoimmune diseases.”
Dr. Clemente leads a team of researchers who use advanced experimental and computational methods to study the microbiome under healthy and disease conditions. For instance, his lab studied the role of gut bacteria in Clostridium difficile infections, inflammatory bowel disease, and autoimmune hepatitis.
Launched in the 2014, the AMP program is a public-private partnership between the NIH, the U.S. Food and Drug Administration (FDA), multiple biopharmaceutical and life science companies, and non-profit and other organizations. The program aims “to transform the current model for developing new diagnostics and treatments.” Other areas of research include Alzheimer’s disease, Parkinson’s disease, and schizophrenia.
AMP® AIM was started in 2021 “to deepen our understanding of the cellular and molecular interactions that lead to inflammation and autoimmune diseases.”
“We are very excited that Dr. Clemente’s team will be playing a pivotal role in this groundbreaking project,” said Alison M. Goate, DPhil, the Jean C. and James W. Crystal Professor and Chair of Genetics and Genomic Sciences at Icahn Mount Sinai. “Understanding how our microbiome interacts with our immune system is key to a better understanding of these debilitating diseases and holds promise for improved treatments in the future.”
Dr. Clemente’s team will work with researchers in the lab of Jose U. Scher, MD, the Steere-Abramson Associate Professor at NYU Langone Health. The Clemente and Scher labs have worked together for several years. Recently, they published a study on how gut bacteria may influence some cases of spondyloarthritis, a type of arthritis that attacks the joints and spine.
In this newly funded study, their teams will try to reconstruct and analyze how the microbiome may work in several autoimmune disorders, including rheumatoid arthritis, systemic lupus erythematosus, psoriasis, psoriatic arthritis, and Sjögren’s disease.
“The AMP AIM program will allow us to identify microbial features that are either shared across different autoimmune and immune conditions or unique for individual forms of these diseases,” Dr. Clemente says. “These studies could help us find more precise matches between diseases and conditions and treatments that are currently available.”
The award, titled “Micro-TeACH (Microbiome Technology and Analytic Center Hub),” will be funded by the National Institutes of Health (AR081034).
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, nearly 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. We are consistently ranked by U.S. News & World Report's Best Hospitals, receiving high "Honor Roll" status, and are highly ranked: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. U.S. News & World Report’s “Best Children’s Hospitals” ranks Mount Sinai Kravis Children's Hospital among the country’s best in several pediatric specialties.